Dunn B E, Vakil N B, Schneider B G, Miller M M, Zitzer J B, Peutz T, Phadnis S H
Department of Pathology, Medical College of Wisconsin, Milwaukee, USA.
Infect Immun. 1997 Apr;65(4):1181-8. doi: 10.1128/iai.65.4.1181-1188.1997.
Helicobacter pylori is a spiral, gram-negative bacterium which causes chronic gastritis and plays a critical role in peptic ulcer disease, gastric carcinoma, and gastric lymphoma. H. pylori expresses significant urease activity which is an essential virulence factor. Since a significant fraction of urease activity is located on the surface of the bacterium, the urease molecule is a logical choice as an antigen for a vaccine; currently recombinant urease apoenzyme is being tested as a vaccine in phase II clinical trials. We have recently demonstrated that urease and HspB (a homolog of the GroEL heat shock protein) become associated with the surface of H. pylori in vitro in a novel manner: these cytoplasmic proteins are released by bacterial autolysis and become adsorbed to the surface of intact bacteria, reflecting the unique characteristics of the outer membrane. To determine if similar mechanisms are operative in vivo, we determined the ultrastructural locations of urease and HspB within bacteria present in human gastric biopsies. Our results demonstrate that both urease and HspB are located within the cytoplasm of all bacteria examined in human gastric biopsies. Interestingly, a significant proportion of the bacteria examined also possessed variable amounts of surface-associated urease and HspB antigen (from 5 to 50% of the total antigenic material), indicating that in vivo, H. pylori has surface characteristics which enable it to adsorb cytoplasmic proteins. This is consistent with our altruistic autolysis model in which H. pylori uses genetically programmed bacterial autolysis to release urease and other cytoplasmic proteins which are subsequently adsorbed onto the surface of neighboring viable bacteria. These observations have important implications regarding pathogenesis and development of vaccines for H. pylori.
幽门螺杆菌是一种螺旋形革兰氏阴性菌,可引起慢性胃炎,在消化性溃疡病、胃癌和胃淋巴瘤中起关键作用。幽门螺杆菌表达显著的脲酶活性,这是一种重要的毒力因子。由于脲酶活性的很大一部分位于细菌表面,脲酶分子作为疫苗抗原是一个合理的选择;目前重组脲酶脱辅基酶正在进行II期临床试验作为疫苗进行测试。我们最近证明,脲酶和HspB(GroEL热休克蛋白的同源物)在体外以一种新的方式与幽门螺杆菌表面结合:这些细胞质蛋白通过细菌自溶释放出来,并吸附到完整细菌的表面,反映了外膜的独特特性。为了确定类似的机制在体内是否起作用,我们确定了人胃活检组织中细菌内脲酶和HspB的超微结构位置。我们的结果表明,在人胃活检组织中检测的所有细菌的细胞质中都存在脲酶和HspB。有趣的是,检测的很大一部分细菌还具有不同数量的表面相关脲酶和HspB抗原(占总抗原物质的5%至50%),这表明在体内,幽门螺杆菌具有使其能够吸附细胞质蛋白的表面特征。这与我们的利他自溶模型一致,在该模型中,幽门螺杆菌利用基因编程的细菌自溶来释放脲酶和其他细胞质蛋白,这些蛋白随后吸附到邻近活细菌的表面。这些观察结果对幽门螺杆菌的发病机制和疫苗开发具有重要意义。